Thorac Cardiovasc Surg 2018; 66(S 01): S1-S110
DOI: 10.1055/s-0038-1627926
Oral Presentations
Sunday, February 18, 2018
DGTHG: Catheter-based Valvular Therapies - AV Valves
Georg Thieme Verlag KG Stuttgart · New York

Hemodynamic Effects of Interventional Edge-to-Edge Mitral Valve Repair in Patients with End-Stage Heart Failure Awaiting Heart Transplantation

N. A. Geis
1   Division of Cardiology, Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany
,
S. T. Pleger
1   Division of Cardiology, Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany
,
R. Bekeredjian
1   Division of Cardiology, Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany
,
E. Chorianopoulos
1   Division of Cardiology, Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany
,
L. Frankenstein
1   Division of Cardiology, Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany
,
A. Ruhparwar
2   Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany
,
H. A. Katus
1   Division of Cardiology, Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany
,
P. Raake
1   Division of Cardiology, Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
22 January 2018 (online)

Objectives: Functional mitral regurgitation is complicating end-stage heart failure and potential heart transplantation by augmenting pulmonary artery pressures. The aim of the present study was to investigate feasibility and hemodynamic effects of interventional edge-to-edge mitral valve repair using the MitraClip device in patients with end-stage heart failure awaiting heart transplantation.

Methods: In this retrospective study, we identified 9 patients suffering from end-stage heart failure listed for heart transplantation in whom moderate-severe or severe functional mitral regurgitation was recognized and treated with interventional edge-to-edge mitral valve repair. In an as-treated analysis twenty-six patients listed for heart transplantation and presenting with moderate-severe or severe functional mitral regurgitation served as controls, 22 in the pre-MitraClip era, and 4 in the MitraClip era with failed implantation. Patients were analyzed at two separate time points: MitraClip group: pre and post procedure (follow-up: 215.2 ± 53.3days), control group: study entry with recognition of moderate-severe or severe functional mitral regurgitation or pre and post failed MitraClip attempt (follow-up: 196.6 ± 46.8 days).

Results: Endovascular mitral valve repair with the MitraClip was feasible and safe in our high-risk end-stage heart failure population. Endovascular mitral valve repair resulted in significant reduction of mitral regurgitation, left atrial diameter, pulmonary artery pressures and NYHA class and improved mixed-venous oxygen saturation. No changes in the control group were observed.

Conclusions: MitraClip implantation as “bridge-to-transplant” strategy in patients with end-stage heart failure and severe functional mitral regurgitation awaiting heart transplantation is feasible and appears to result in favorable hemodynamic effects.